References
Appell RA, Sand P, Dmochowski R, et al.: Prospective, randomized, controlled trial of extended-release oxybutynin, chloride, and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001, 76:358–363.
Diokno AC, Appell RA, Sand PK, et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial. Mayo Clin Proc 2003, 78:687–695.
MacDiarmid SA: Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003, 4:446–451.
Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809–1812.
Gleason DM, Susset J, White C, et al.: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999, 54:420–423.
Rights and permissions
About this article
Cite this article
Staskin, D.R., Dmochowski, R.R. & Wein, A.J. Solifenacin versus tolterodine— A head-to-head study: Finally! but not final?. Curr Urol Rep 6, 403–404 (2005). https://doi.org/10.1007/s11934-005-0032-3
Issue Date:
DOI: https://doi.org/10.1007/s11934-005-0032-3